The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Technology-enhanced palliative care for patients with cancer on phase 1 clinical trials.
 
Ishwaria Mohan Subbiah
Consulting or Advisory Role - MedImmune (I)
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I)
Travel, Accommodations, Expenses - Bayer (I); MedImmune (I); Novartis (I); PharmaMar (I)
 
Jaya Sheela Amaram-Davila
No Relationships to Disclose
 
Angelique Wong
No Relationships to Disclose
 
Kaoswi Karina Shih
No Relationships to Disclose
 
Aimee Elizabeth Anderson
No Relationships to Disclose
 
Tito R. Mendoza
No Relationships to Disclose
 
Loretta A. Williams
Consulting or Advisory Role - PledPharma
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Akhila Sunkepally Reddy
No Relationships to Disclose
 
Manju P Joy
No Relationships to Disclose
 
Katie M Harnden
No Relationships to Disclose
 
Melissa L Gaffney
No Relationships to Disclose
 
Zeena Shelal
No Relationships to Disclose
 
Rama Maddi
No Relationships to Disclose
 
Christina LD Nelson
No Relationships to Disclose
 
Vera J De la Cruz
No Relationships to Disclose
 
Saline Liselle Elder
No Relationships to Disclose
 
Desiree Q Ray
No Relationships to Disclose
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Eduardo Bruera
Research Funding - Helsinn Healthcare (Inst)